Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?

Suzman D, Eisenberger M.

Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. No abstract available.

PMID:
24751214
2.

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F.

Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056.

3.

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, Thalmann G, Cassoly E, Millman R, Matheson D, Schiavone F, Spears MR, Parmar MK, James ND.

Eur Urol. 2014 Nov;66(5):799-802. doi: 10.1016/j.eururo.2014.05.038.

5.

Burden of disease matters when it comes to systemic therapy for prostate cancer.

Harrison MR, Armstrong AJ.

Eur Urol. 2015 Mar;67(3):448-50. doi: 10.1016/j.eururo.2014.02.032. No abstract available.

PMID:
24612662
6.

Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor.

Suzman DL, Eisenberger MA.

Eur Urol. 2014 May;65(5):884-6. doi: 10.1016/j.eururo.2013.10.002. No abstract available.

8.

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN.

Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030.

PMID:
24508071
9.

Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.

Petrioli R, Francini E, Laera L, Fiaschi AI, Ponchietti R, Roviello G.

Cancer Chemother Pharmacol. 2015 Sep;76(3):439-45. doi: 10.1007/s00280-015-2803-y. Review.

PMID:
26082421
10.

Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.

Inoue K, Shishido A, Vaccaro N, Jiao J, Stieltjes H, Bernard A, Yu M, Chien C.

Cancer Chemother Pharmacol. 2015 Jan;75(1):49-58. doi: 10.1007/s00280-014-2616-4.

PMID:
25344090
11.

Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer.

Manenschijn L, Hamberg P.

Acta Oncol. 2016 May;55(5):656-8. doi: 10.3109/0284186X.2015.1118657. No abstract available.

PMID:
27046420
12.
13.

Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.

Harshman LC, Taplin ME.

Adv Ther. 2013 Aug;30(8):727-47. doi: 10.1007/s12325-013-0050-3. Review.

14.

A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.

Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.

Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070.

PMID:
25981621
15.

Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?

Geynisman DM, Ross EA, Plimack ER.

Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. No abstract available.

PMID:
26116295
16.

Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.

Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, Li J, Kheoh T, Haqq CM, Fizazi K.

Eur Urol. 2014 May;65(5):875-83. doi: 10.1016/j.eururo.2013.09.005.

PMID:
24099659
17.

Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

Zhang T, Zhu J, George DJ, Armstrong AJ.

Expert Opin Pharmacother. 2015 Mar;16(4):473-85. doi: 10.1517/14656566.2015.995090. Review.

PMID:
25534660
18.

Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.

Arrabal-Martín M, Anglada-Curado F, Cózar-Olmo JM, Soler-Martínez J, Moreno-Jiménez J, Castiñeiras-Fernández J, Ledo-Cepero MJ, Beardo-Villar P, Requena-Tapia MJ, Zuluaga-Gómez A; Grupo AAyEU..

Actas Urol Esp. 2014 Jun;38(5):327-33. doi: 10.1016/j.acuro.2013.10.008. Review. English, Spanish.

PMID:
24342031
19.

Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS.

J Clin Endocrinol Metab. 2012 Feb;97(2):507-16. doi: 10.1210/jc.2011-2189.

PMID:
22170708
20.

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.

Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064.

PMID:
26306637
Items per page

Supplemental Content

Support Center